The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) is a national network for providers that collects longitudinal diagnostic and therapeutic clinical data, including cognitive and functional assessments. ALZ-NET will offer better insight into the long-term health outcomes for patients who receive new FDA-approved Alzheimer's drugs and therapies.

With access to this real-world data, health care providers can improve diagnosis and patient care. Meanwhile, researchers can advance the science behind future Alzheimer's and dementia treatments.

A word from Maria C. Carrillo, Ph.D., Chief Science Officer, Alzheimer's Association

"We are entering a new phase of Alzheimer's treatment. ALZ-NET is the tool that will help us translate therapies into care that provides the most benefit to people living with the disease and their caregivers, in all communities. In collaboration with partners and scientific leaders, we are looking to develop the future of treatment and diagnostics by collecting data in real-world settings."

Benefits of the Alzheimer's Network for Treatment and Diagnostics

  • Stay on the leading edge of medical and scientific advancements. ALZ-NET is designed to grow and document the use of new drugs as they are approved and implemented in care.
  • Be part of building the future of Alzheimer's treatment and care through the collection of substantive data. ALZ-NET will gather diagnostic and longitudinal patient data, including measures of cognition, function and safety.
  • Advance the Alzheimer's and dementia treatment field as a whole by sharing de-identified patient data, brain scans and blood samples with the research community.
  • Develop a regulatory-grade national network for enrollment and data collection, including training and support for health care providers and clinicians.

How ALZ-NET works: overview and next steps

Learn more about the launch of the Alzheimer's Network for Treatment and Diagnostics in a recorded session with principal investigators during the Alzheimer's Association International Conference (AAIC) in August 2022.

Watch the 45-minute session for updates on progress so far, frequently asked questions, and how to become a site or affiliated study as part of ALZ-NET.

How to get involved in ALZ-NET

This will be a provider enrolled network. Clinicians and specialists who participate in ALZ-NET will register their patients' experiences with new FDA-approved Alzheimer’s disease therapies, including safety and effectiveness. View the ALZ-NET Protocol Synopsis (PDF).

To start the process of becoming a participating site, please fill out the ALZ-NET Site Feasibility and Registration Form. It takes about 10 minutes to complete and asks for information about your site's patient population, imaging facility and staffing.

Begin Site Registration

For questions about timing and participation, or other inquiries about ALZ-NET, please contact


Alzheimer's Association
American College of Radiology
Critical Path Institute
Department of Biostatistics, Brown University School of Public Health
American Society of Neuroradiology